Synapse - Gopakumar Iyer

Search Within

Gopakumar Vasudeva Iyer

Results (342)

Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016

Correspondence

Iyer, G.; Bochner, B. H.; Van Allen, E. M.; Solit, D. B.; Rosenberg, J. E.
European Urology (2021)

Fulltext@MSK | Save

Lessons from the study of exceptional responders

Editorial

Elzein, A.; Iyer, G.; Solit, D. B.
Cancer Cell (2021)

Fulltext@MSK | Save

MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy

Meeting Abstract

Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma

Journal Article

Teo, M. Y.; Mota, J. M.; Whiting, K. A.; Li, H. A.; Funt, S. A.; Lee, C. H.; Solit, D. B.; Al-Ahmadie, H.; Milowsky, M. I.; Balar, A. V.; more...
European Urology (2020)

Fulltext@MSK | Save

Germ cell tumor molecular heterogeneity revealed through analysis of primary and metastasis pairs

Journal Article

Cheng, M. L.; Donoghue, M. T. A.; Audenet, F.; Wong, N. C.; Pietzak, E. J.; Bielski, C. M.; Isharwal, S.; Iyer, G.; Funt, S.; Bagrodia, A.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)

Meeting Abstract

Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations

Meeting Abstract

Janku, F.; Elez, E.; Iyer, G.; Yamamoto, N.; Tan, D. S. W.; Stathis, A.; Stammberger, U. M.; Evans, H.; Seroutou, A.; Mais, A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion

Meeting Abstract

Cleary, J. M.; Iyer, G.; Oh, D. Y.; Mellinghoff, I. K.; Goyal, L.; Ng, M. C. H.; Meric-Bernstam, F.; Matos, I.; Chao, T. Y.; Sarkouh, R. A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naive, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

Meeting Abstract

Msaouel, P.; Siefker-Radtke, A. O.; Sweis, R.; Mao, S.; Rosenberg, J. E.; Vaishampayan, U. N.; Rezazadeh Kalebasty, A.; Pili, R.; Bupathi, M.; Nordquist, L. T.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations

Meeting Abstract

Schuler, M.; Tabernero, J.; Massard, C.; Vasudeva Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save